AwesomeCapital
Search This Blog
Monday, November 11, 2024
RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold
Due to Single SAE of Severe Liver Injury
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities
https://www.globenewswire.com/news-release/2024/11/11/2978268/0/en/Based-on-Recent-FDA-Feedback-RAPT-Therapeutics-Stops-Zelnecirnon-Program-Following-Clinical-Hold-Due-to-Single-SAE-of-Severe-Liver-Injury.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.